AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17207911 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 110
Study 14747389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid
Number of subjects: 510
Study 14747389 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid
Number of subjects: 510
Study 14747389 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg folic acid
Number of subjects: 510
Study 14747389 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline tHcy (quartiles)
Number of subjects: 510
Study 14747389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (all groups combined)
Number of subjects: 510
Study 11259518 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention (daily practice with audiotaped instructions)
Number of subjects: 46
Study 11259518 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 46
Study 9676351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoretard Capsules
Number of subjects: 19
Study 9676351 — intervention group
Group type: COMPARATOR
Intervention: Capsule formulation from the US market
Number of subjects: 19
Study 7990375 — intervention group
Group type: EXPERIMENTAL
Intervention: Veroshpiron (50-100 mg/day)
Number of subjects: 39
Study 2904461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin alone
Number of subjects: 0
Study 2904461 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime and metronidazole
Number of subjects: 0
Study 2904461 — intervention group
Group type: COMPARATOR
Intervention: Historical placebo controls
Number of subjects: 0
Study 29554321 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated frameless robotic SRS based on SPACE imaging sequence
Number of subjects: 200
Study 29554321 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated frameless robotic SRS based on MPRAGE imaging sequence
Number of subjects: 200
Study 29554321 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival assessment
Number of subjects: 200
Study 29554321 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and neurocognition evaluation every 3 months using CANTAB tests and EORTC questionnaires
Number of subjects: 200
Study 27393707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture
Number of subjects: 0
Study 24998619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 35
Study 24998619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 35
Study 23117488 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings (GCS)
Number of subjects: 1971
Study 23117488 — intervention group
Group type: COMPARATOR
Intervention: DVT rates
Number of subjects: 1971
Study 21628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 569
Study 21628668 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir-ritonavir
Number of subjects: 569
Study 21628668 — intervention group
Group type: EXPERIMENTAL
Intervention: X4 viruses
Number of subjects: 569
Study 21628668 — intervention group
Group type: COMPARATOR
Intervention: R5 strains
Number of subjects: 569
Study 21628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 569
Study 21628668 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count recovery
Number of subjects: 569
Study 19180852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully trained group
Number of subjects: 20
Study 19180852 — intervention group
Group type: COMPARATOR
Intervention: Minimally trained group
Number of subjects: 20
Study 18250489 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliton (carvedilol) starting dose 3.125 mg twice daily, increased to target dose 25 mg twice daily over 6 months
Number of subjects: 20
Study 15564697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (200 mg/day)
Number of subjects: 23
Study 15564697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (200 mg/day) + Aprindine (40 or 60 mg/day)
Number of subjects: 23
Study 15564697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil + Aprindine
Number of subjects: 23
Study 12775190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with orbitofrontal lesions
Number of subjects: 0
Study 12775190 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 12775190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with damage to the dorsolateral prefrontal cortex
Number of subjects: 0
Study 10365144 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy including interferon-alpha 2a, interleukin-2, 5-fluorouracil (5-FU), isotretinoin (ISO), and vinblastin (VBL)
Number of subjects: 0
Study 7673284 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage using the Autovac Postoperative Orthopaedic Autotransfusion Canister
Number of subjects: 232
Study 7673284 — intervention group
Group type: COMPARATOR
Intervention: Closed suction drainage using the Hemovac system
Number of subjects: 232
Study 1967561 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg b.i.d. for 3 months
Number of subjects: 617
Study 1967561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 1967561 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 617
Study 1967561 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.125 mg b.i.d.
Number of subjects: 617
Study 7375188 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 74
Study 7375188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29343201 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant juice (500 mg of polyphenols)
Number of subjects: 9
Study 28825235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride aerosol spray (n=66)
Number of subjects: 126
Study 28825235 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol spray (n=60)
Number of subjects: 126
Study 26074365 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administered through a buccal window approach
Number of subjects: 24
Study 26074365 — intervention group
Group type: COMPARATOR
Intervention: Conventional management via creation of a window on the buccal wall and curettage of the walls of the defect
Number of subjects: 24
Study 25309087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (1 cone, 3 treatments/week)
Number of subjects: 166
Study 25309087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (2 cones, 3 treatments/week)
Number of subjects: 166
Study 25309087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (1 cone, 6 treatments/week)
Number of subjects: 166
Study 25309087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (2 cones, 6 treatments/week)
Number of subjects: 166
Study 25309087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake‐separated moxibustion (frequency comparison)
Number of subjects: 166
Study 20937671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 2×1000 mg + MTX
Number of subjects: 755
Study 20937671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 2×500 mg + MTX
Number of subjects: 755
Study 20937671 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 755
Study 19374299 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-strand hamstring tendons
Number of subjects: 34
Study 19374299 — intervention group
Group type: COMPARATOR
Intervention: bone-patellar tendon-bone graft
Number of subjects: 34
Study 17305661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg
Number of subjects: 99
Study 17305661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 99
Study 17305661 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.6 mg/kg
Number of subjects: 99
Study 15665624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized adjuvant peptide vaccinations derived from MelanA/MART1, gp100, and tyrosinase with GM-CSF
Number of subjects: 10
Study 15665624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized adjuvant peptide vaccinations with GM-CSF
Number of subjects: 10
Study 11391090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 9281928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest (napping)
Number of subjects: 124
Study 9281928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimuli
Number of subjects: 124
Study 9281928 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of odors
Number of subjects: 124
Study 8471126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3086989 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgrow culture
Number of subjects: 0
Study 3086989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonozyme test
Number of subjects: 0
Study 3086989 — intervention group
Group type: COMPARATOR
Intervention: Thayer-Martin cultures
Number of subjects: 0
Study 30353706 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 lb weight gain over 7 days
Number of subjects: 119
Study 30353706 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dyspnoea over 7 days
Number of subjects: 119
Study 26499966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive‐PD intervention
Number of subjects: 339
Study 26499966 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-month wait-list usual-care)
Number of subjects: 339
Study 23639624 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with slow VT
Number of subjects: 426
Study 23639624 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with fast VT/VF
Number of subjects: 426
Study 23639624 — intervention group
Group type: COMPARATOR
Intervention: ICD patients
Number of subjects: 426
Study 21247664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 20
Study 21247664 — intervention group
Group type: COMPARATOR
Intervention: Biafine Topical Emulsion (BTE)
Number of subjects: 20
Study 19556227 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of elasticity and stiffness using echo-tracking ultrasound system (Diamove)
Number of subjects: 61
Study 17628972 — intervention group
Group type: EXPERIMENTAL
Intervention: AR group (with allergic rhinitis)
Number of subjects: 56
Study 17628972 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR group (without allergic rhinitis)
Number of subjects: 56
Study 17628972 — intervention group
Group type: EXPERIMENTAL
Intervention: AR group
Number of subjects: 56
Study 17628972 — intervention group
Group type: EXPERIMENTAL
Intervention: NAR group
Number of subjects: 56
Study 17628972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 17628972 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA-3 positive-staining rate
Number of subjects: 56
Study 15117996 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture twice per week for 4 weeks
Number of subjects: 31
Study 15117996 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture once per week for 6 weeks
Number of subjects: 31
Study 11451008 — intervention group
Group type: EXPERIMENTAL
Intervention: RPU + TIAR
Number of subjects: 380
Study 11451008 — intervention group
Group type: COMPARATOR
Intervention: RPU alone
Number of subjects: 380
Study 9012642 — intervention group
Group type: EXPERIMENTAL
Intervention: E4 allele carriers
Number of subjects: 260
Study 9012642 — intervention group
Group type: COMPARATOR
Intervention: E2 allele carriers
Number of subjects: 260
Study 9012642 — intervention group
Group type: COMPARATOR
Intervention: E3 allele carriers
Number of subjects: 260
Study 7970216 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon 4 allele
Number of subjects: 88
Study 7970216 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon 4 homozygote
Number of subjects: 88
Study 3475231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg or 2 mg PGE2 intravaginally at an interval of 6 hours
Number of subjects: 99
Study 3475231 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin and amniotomy
Number of subjects: 99
Study 3475231 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 induction
Number of subjects: 99
Study 3475231 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin group
Number of subjects: 99
Study 2129320 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin 20 mg b.i.d.
Number of subjects: 20
Study 2129320 — intervention group
Group type: EXPERIMENTAL
Intervention: cholestyramine 16‐24 g/day
Number of subjects: 20
Study 2129320 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 2129320 — intervention group
Group type: COMPARATOR
Intervention: control group (age‐ and sex‐matched)
Number of subjects: 20
Study 973981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5-10 mg three times daily)
Number of subjects: 45
Study 973981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (25-50 mg three times daily)
Number of subjects: 45
Study 973981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30337697 — intervention group
Group type: EXPERIMENTAL
Intervention: FBA
Number of subjects: 111
Study 30337697 — intervention group
Group type: COMPARATOR
Intervention: BuCy2
Number of subjects: 111
Study 27842179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 97/103 mg twice daily
Number of subjects: 8399
Study 27842179 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 8399
Study 27842179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 97/103 mg twice daily (newly started MRA)
Number of subjects: 8399
Study 27842179 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily (newly started MRA)
Number of subjects: 8399
Study 26291258 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (20mg/ml)
Number of subjects: 15
Study 26291258 — intervention group
Group type: COMPARATOR
Intervention: Keloid excisions without triamcinolone
Number of subjects: 15
Study 24010637 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate plus calcium and vitamin D
Number of subjects: 80
Study 24010637 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus calcium and vitamin D
Number of subjects: 80
Study 21784746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-selected ventricular tachyarrhythmia detection, anti-tachycardia pacing, and SVT discriminator parameters
Number of subjects: 1600
Study 21784746 — intervention group
Group type: COMPARATOR
Intervention: Standard arrhythmia detection and therapy approaches (Control group)
Number of subjects: 1600
Study 20143017 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group (first premolar extraction)
Number of subjects: 120
Study 20143017 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction group
Number of subjects: 120
Study 16565252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment to normalize hemoglobin (Hgb) levels.
Number of subjects: 0
Study 16565252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >12 g/dl.
Number of subjects: 0
Study 16565252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment to achieve Hgb >11 g/dl.
Number of subjects: 0
Study 16565252 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (EPO) treatment for normalization of hematocrit.
Number of subjects: 0
Study 16565252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) treatment.
Number of subjects: 0
Study 14730403 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 19
Study 14730403 — intervention group
Group type: COMPARATOR
Intervention: (111)In-granulocyte scintigraphy
Number of subjects: 19
Study 11158750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 409
Study 11158750 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 409
Study 9279532 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms subcutaneously (s.c.)
Number of subjects: 28
Study 9279532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7848391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalad catheter insertion (group 1)
Number of subjects: 105
Study 7848391 — intervention group
Group type: COMPARATOR
Intervention: Caudad catheter insertion (group 2)
Number of subjects: 105
Study 3774016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy with low-dose prednisone (7.5 mg/day) and CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 491
Study 3774016 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFp + T (chemotherapy plus low-dose prednisone and tamoxifen)
Number of subjects: 491
Study 3774016 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (p + T)
Number of subjects: 491
Study 3774016 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after total mastectomy and axillary clearance (observation group)
Number of subjects: 491
Study 30064926 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 1215
Study 28815256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen capsules
Number of subjects: 500
Study 28815256 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 500
Study 25661407 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling to reduce total cholesterol concentration
Number of subjects: 1062
Study 25661407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 1062
Study 25661407 — intervention group
Group type: COMPARATOR
Intervention: Control group (familial risk children)
Number of subjects: 1062
Study 25661407 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with high Lp(a) concentrations (>500 mg/L) in the intervention group
Number of subjects: 1062
Study 23484827 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence during CPR (intervention group)
Number of subjects: 570
Study 23484827 — intervention group
Group type: COMPARATOR
Intervention: Standard practice regarding family presence (control group)
Number of subjects: 570
Study 20857138 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCP users tested at Day 1 and Day 14 of their cycle
Number of subjects: 38
Study 20857138 — intervention group
Group type: COMPARATOR
Intervention: Non-MOCP users tested at menstruation and ovulation
Number of subjects: 38
Study 18204335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (initiated at 10 mg/d, flexibly dosed at 5-30 mg/d)
Number of subjects: 373
Study 18204335 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 373
Study 18204335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 16728480 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiochemotherapy (RT-CT) - two cycles of platinum etoposide followed by two cycles of platinum-vinorelbine
Number of subjects: 173
Study 16728480 — intervention group
Group type: COMPARATOR
Intervention: Sequential radiochemotherapy (RT-CT) - three cycles of chemotherapy followed by radiotherapy
Number of subjects: 173
Study 12410708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleo Performance lamps (conventional UV A lamps)
Number of subjects: 34
Study 12410708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleo Natural lamps (new higher UV B-emitting lamps)
Number of subjects: 34
Study 9892032 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-134a albuterol sulfate (108 microg of albuterol sulfate, equivalent to 90 microg of albuterol base)
Number of subjects: 22
Study 9892032 — intervention group
Group type: COMPARATOR
Intervention: CFC albuterol (equivalent doses)
Number of subjects: 22
Study 8655205 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (3 x 0.5g/d)
Number of subjects: 165
Study 8655205 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (3 x 2g/d) plus Piperacillin (3 x 4g/d)
Number of subjects: 165
Study 8655205 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 165
Study 8655205 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus Piperacillin
Number of subjects: 165
Study 2363736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (27 mg/kg EPA and 18 mg/kg DHA)
Number of subjects: 49
Study 2363736 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil (54 mg/kg EPA and 36 mg/kg DHA)
Number of subjects: 49
Study 2363736 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (6.8 gm of oleic acid)
Number of subjects: 49
Study 2363736 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (low-dose, high-dose, and olive oil)
Number of subjects: 49
Study 348096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 22
Study 348096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 22
Study 31750698 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL (goal prompts/support)
Number of subjects: 0
Study 31750698 — intervention group
Group type: COMPARATOR
Intervention: TRACK (self‐monitoring of alcohol use)
Number of subjects: 0
Study 31750698 — intervention group
Group type: COMPARATOR
Intervention: PLAN (feedback on drinking plans and DD)
Number of subjects: 0
Study 31750698 — intervention group
Group type: COMPARATOR
Intervention: USE (postdrinking feedback on alcohol consumed)
Number of subjects: 0
Study 31750698 — intervention group
Group type: COMPARATOR
Intervention: COMBO (i.e., 4 interventions combined)
Number of subjects: 0
Study 28294700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 10
Study 28294700 — intervention group
Group type: COMPARATOR
Intervention: Control Sedentary (SED)
Number of subjects: 10
Study 26725184 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg orally daily)
Number of subjects: 59